The industry has learned how the ball bounces—now it must decide where to play next. | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that the first patient has been dosed ...
In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...
Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine ...
Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this year, calling on the industry to reinvent R&D, design enduring ...
Leveraging traditional medical knowledge and integrating it with modern, cutting-edge technologies, the company is developing ...
Biopharma enters 2026 amid continuing scientific progress and accelerating deal activity, yet its business model is under pressure across every facet of the value chain. Investors are taking note: ...
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized ...
Zacks Investment Research on MSN
Sutro Biopharma (STRO) soars 5.9%: Is further upside left in the stock?
Sutro Biopharma, Inc. (STRO) shares rallied 5.9% in the last trading session to close at $15.8. This move can be attributable ...
Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...
Biopharma stocks may rally in 2026 as M&A heats up and drug pricing uncertainty fades—see why UBS expects big pharma to buy biotech now—read more.
Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results